
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions โ written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Bowel obstruction medical therapy
Introduction
Overview
Overview
The mainstay treatment of bowel obstruction is surgical and non-operative management. The role of medical therapy is supportive and is limited by palliative pain management in cancer patients, fluid and electrolyte replenishment, decreasing abdominal distension, peritumoral edema, intraluminal secretions, peristaltic movements, and control of nausea and vomiting.
Medical Therapy
Medical Therapy
The mainstay treatment of bowel obstruction is surgical and non-operative management. The role of medical therapy is supportive and is limited by control of vomiting and nausea, fluid and electrolyte replenishment, and palliative pain management in cancer patients. Glucocorticoids, octreotide and anticholinergic agents can be used to decrease abdominal distension, peritumoral edema, intraluminal secretions, and peristaltic movements. Antibiotics also play a role in treating infections but are not routinely recommended.[1][2][3][4][5][6][7][8][9]
- 1 Antiemetics
- 1.1 Antiemetics in cancer patients
- 1.1.1 Adult
- Note (1): Used in conjunction with nasogastric decompression
- Preferred regimen (1): Haloperidol 0.5 -2 mg and up to 20 mg PO q6h IV or SC
- Preferred regimen (2): Dexamethasone 4 mg q12h IV or SC
- Preferred regimen (3): Octreotide 0.1 mg and up to 0.3 mg q8h IV or SC
- Alternative regimen (1): Hyoscine (scopolamine) hydrobromide 0.2 – 0.4 mg q6 – 8h SC or transdermal
- Alternative regimen (2): Chlorpromazine, prochlorperazine, or cyclizine 0.2 – 0.4 mg q6 – 8h SC or IV or rectally
- Alternative regimen (3): Octreotide 300 ยตg once daily
- Alternative regimen (4): Metoclopramide 30 – 60 mg q24h SC
- 1.1.2 Antiemetics in non-cancer patients
- Preferred regimen (1): Promethazine 12.5-25 mg q4 – 6h PRN or PO, alternatively 12.5-25 mg q4 – 6h IV or IM
- Preferred regimen (2): Ondansetron 4 – 8 mg q8-12hr PO or IV
- 1.1.3 Pediatric
- 1.1.3.1 Children 1 month – 12 years of age
- Preferred regimen (1): Ondansetron <40 kg, 0.1 mg/kg IV
- Preferred regimen (2): Ondansetron >40 kg, 4 mg IV
- 1.1.3.1 Children < 2 years of age
- Preferred regimen (1): Promethazine – contraindicated
- 1.1.3.2 Children > 2 years of age
- Preferred regimen (1): Promethazine 0.25-1 mg/kg PO/PR q4-6hr; not > 25 mg
- 1.1.3.2 Children > 12 years of age
- Preferred regimen (1): Ondansetron 4 mg IV/IM or 16 mg PO 1 hr
- 1.1.3.1 Children 1 month – 12 years of age
- 1.1.1 Adult
- 1.1 Antiemetics in cancer patients
- 2 Fluid and electrolyte replacement
- 2.1 Fluid replacement
- 2.1.1 Adult
- Parenteral regimen
- Preferred regimen (1): Isotonic saline or lactated Ringer’s solution 1 – 2 L IV initially, in addition to administration of fluid equal to the urine output plus insensible fluid losses (approx. 30 – 50 ml)
- Parenteral regimen
- 2.2 Electrolyte replacement
- Hyponatremia
- Hypokalemia
- Preferred regimen (1): Potassium 40 mEq/L or 3.0 g per L not > 80 mEq/L
- Note (1): Replacement is only necessary if deficit continues for >48h, or in excess of 2L in 24h
- Hypochloremia
- Preferred regimen (1): Chloride 40 mEq/L not> 80 mEq/L
- 2.1.1 Adult
- 2.1 Fluid replacement
- 3 Pain management in cancer/non-cancer patients
- 3.1 Non-opioids
- 3.1.1 Adult
- Preferred regimen (1): Acetaminophen 325โ1000 mg PO q4โ6h PRN
- Alternative regimen (2): Aspirin 325โ650 mg PO q4h PRN
- Alternative regimen (3): Diclofenac 50 mg PO BID-TID
- Alternative regimen (3): Etodolac 200โ400 mg PO q6โ8h
- Alternative regimen (4): Ibuprofen 400โ600 mg POq 4โ6h PRN
- Alternative regimen (5): Indomethacin 25โ50 mg PO TID
- Alternative regimen (6): Ketoprofen 25โ50 mg PO q6hโq8h
- Alternative regimen (7): Ketorolac 10 mg PO q4โ6h PRN or 30 mg IV/IM q6h
- Alternative regimen (8): Meclofenamate 50โ100 mg PO q4โ6h PRN
- Alternative regimen (9): Mefenamic acid 250 mg PO q4โ6 PRN
- Alternative regimen (10): Meloxicam 7.5โ15 mg PO once daily
- Alternative regimen (11): Nabumetone 100โ2000 mg once daily
- Alternative regimen (12): Naproxen 250โ500 mg PO BID
- Alternative regimen (13): Oxaprozin 1200 mg PO once daily
- Alternative regimen (14): Piroxicam 20 mg PO once daily
- Alternative regimen (15): Sulindac 150โ200 mg PO BID
- Alternative regimen (16): Tolmetin 200โ600 mg PO BID-TID
- Alternative regimen (17): Tramadol 50โ100 mg PO q4โ6h PRN; 100 โ 300 mg QD for SR
- Alternative regimen (18): Celecoxib 200 mg PO BID
- 3.1.1 Adult
- 3.2 Opioids
- 3.2.1 Adult
- Preferred regimen (1): Morphine sulfate 10โ30 mg q3โ4h PO
- Alternative regimen (1.2): Rectal suppository; 10โ20 mg q4h
- Alternative regimen (1.3): PRN; 2.5โ10 mg q2โ6h
- Alternative regimen (1.4): Epidural; 3โ5 mg once, then 0.1โ0.7 mg/hr
- Alternative regimen (1.5): Intrathecal; start 100:1 IT-to-IV, then titrate to pain
- Alternative regimen (1.6): Controlled release tab 15โ30 mg q8โ12h
- Alternative regimen (1.7): Sustained release tab 15โ30 mg q8โ12h
- Alternative regimen (1.8): Extended release capsule 20 mg q24h, may increase by 20 mg increments every other day
- Alternative regimen (1.9): Extended release capsule 30 mg q24h, may increase by 30 mg increments q4days (max 1600 mg/d)
- Alternative regimen (2): Codeine 15โ60 mg q4โ6h (max 60 mg/d)
- Alternative regimen (3): Dilaudid 2โ8 mg q3-4h for PO and PR
- Alternative regimen (4): Roxycodone 5โ30 mg q4h
- Alternative regimen (5): Oxycontin 10โ160 mg q12h
- Alternative regimen (6): Opana 5โ10 mg q4โ6h
- Alternative regimen (7): Opana extended release 5โ40 mg q12h
- Alternative regimen (8): Propoxyphene HCl 65 mg q4h (max 390 mg/24h)
- Alternative regimen (9): Methadone 2.5โ10 mg q3-6h
- Note (1): Has very long half-life (8โ60 hours)
- Alternative regimen (10): Meperidine 50โ150 mg q3โ4h
- Note (2): Decrease dose if given IV, administer slow or via PCA. Not recommended for chronic use.
- Alternative regimen (11): Fentanyl 25โ100 mcg q1โ2h or 0.5โ1.5 mcg/kg/hr IV infusion via PCA
- Alternative regimen (12): Actiq; start with 200 mcg for breakthrough pain episodes, then titrate to pain
- Alternative regimen (13): Duragesic 25 mcg/h q72hr, may increase q3โ6days
- 3.2.1 Adult
- 3.1 Non-opioids
- 4 Anti-edema
- 4.1 Glucocorticoids
- 4.1.1 Adult
- Preferred regimen (1): Dexamethasone 6 – 16 mg IV or SC daily for 3 – 5 days, not > 7 days
- Alternative regimen (1): Prednisolone 15 – 50 mg IV or SC daily for 3 – 5 days, not > 7 days
- 4.1.1 Adult
- 4.1 Glucocorticoids
- 5 Anti-secretion, anti-peristaltic, and anti-emetic
- 5.1 Anticholinergics
- Preferred regimen (1): Hyoscine 10 – 20 mg IM or IV daily
- Alternative regimen (2): Glycopyrrolate 0.004 mg/kg IM or IV
- 5.1 Anticholinergics
- 6 Infection management
- 6.1 Antibiotics
- 6.1.1 Adult
- Preferred regimen (1): Cefazolin 2 g IV q12hr severe infection, 3 g IV q12hr life-threatening infection
- Alternative regimen (2): Cefoxitin 1 g IV q4hr or 2 g IV q6-8hr severe infection, 6-8 g/day maximum in life threatening
- Alternative regimen (3): Cefotetan 2 g IV q12hr severe infection, 3 g IV q12hr life-threatening infection
- Alternative regimen (4): Cefuroxime 1.5 g IV/IM q8hr severe infection; q6hr in life-threatening circumstances
- Alternative regimen (5): Meropenem 1 g IV q8hr severe infection; not > 2 g IV q8hr
- 6.1.2 Pediatric
- 6.1.2.1 Neonate < 7 days old
- Preferred regimen (1): Cefazolin 40 mg/kg q12h IV or IM daily divided
- Alternative regimen (2): Cefuroxime 100 mg/kg q12h IV or IM daily divided
- Alternative regimen (3): Meropenem 20 mg/kg q8h IV; not > 1 g q8h
- 6.1.2.2 Infants > 7 days old
- Preferred regimen (1): Cefazolin 25-100 mg/kg q6-8h IV or IM daily divided; not > 6 g daily
- Alternative regimen (2): Cefoxitin 80-160 mg/kg q4-6h IV daily divided
- Alternative regimen (3): Cefotetan 40-80 mg/kg q12h IV or IM daily divided
- Alternative regimen (4): Cefuroxime 150 mg/kg q8h IV or IM daily divided
- Alternative regimen (5): Meropenem 20 mg/kg q8h IV; not > 1 g q8h
- 6.1.2.1 Neonate < 7 days old
- 6.1.1 Adult
- 6.1 Antibiotics
- 7 Prokinetics
- Preferred regimen (1): Metoclopramide 10 mg q4h SC or 60 – 200 mg SC daily continuous injection
- Note (1): Contraindicated in complete bowel obstruction
- Alternative regimen (2): Domperidone 10 mg PO QID
- Preferred regimen (1): Metoclopramide 10 mg q4h SC or 60 – 200 mg SC daily continuous injection
References
References
- โ Sagar PM, MacFie J, Sedman P, May J, Mancey-Jones B, Johnstone D (1995). “Intestinal obstruction promotes gut translocation of bacteria”. Dis. Colon Rectum. 38 (6): 640โ4. PMIDย 7774478.
- โ LE QUESNE LP (1955). “Fluid balance in intestinal obstruction”. Postgrad Med J. 31 (355): 227โ33. PMCย 2500705. PMIDย 14371195.
- โ Khoo D, Hall E, Motson R, Riley J, Denman K, Waxman J (1994). “Palliation of malignant intestinal obstruction using octreotide”. Eur. J. Cancer. 30A (1): 28โ30. PMIDย 7511400.
- โ Spears H, Petrelli NJ, Herrera L, Mittelman A (1988). “Treatment of bowel obstruction after operation for colorectal carcinoma”. Am. J. Surg. 155 (3): 383โ6. PMIDย 3344898.
- โ Ripamonti CI, Easson AM, Gerdes H (2008). “Management of malignant bowel obstruction”. Eur. J. Cancer. 44 (8): 1105โ15. doi:10.1016/j.ejca.2008.02.028. PMIDย 18359221.
- โ Blair SL, Chu DZ, Schwarz RE (2001). “Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer”. Ann. Surg. Oncol. 8 (8): 632โ7. PMIDย 11569777.
- โ Higashi H, Shida H, Ban K, Yamagata S, Masuda K, Imanari T, Yamamoto T (2003). “Factors affecting successful palliative surgery for malignant bowel obstruction due to peritoneal dissemination from colorectal cancer”. Jpn. J. Clin. Oncol. 33 (7): 357โ9. PMIDย 12949063.
- โ Frank C (1997). “Medical management of intestinal obstruction in terminal care”. Can Fam Physician. 43: 259โ65. PMCย 2255220. PMIDย 9040913.
- โ Mercadante S, Ferrera P, Villari P, Marrazzo A (2004). “Aggressive pharmacological treatment for reversing malignant bowel obstruction”. J Pain Symptom Manage. 28 (4): 412โ6. doi:10.1016/j.jpainsymman.2004.01.007. PMIDย 15471659.
โโ
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
